Cilostazol Improves Proangiogenesis Functions in Human Early Endothelial Progenitor Cells through the Stromal Cell-Derived Factor System and Hybrid Therapy Provides a Synergistic Effect<i> In Vivo</i>

<div>Schematic representation of the effects of cilostazol on proangiogenic functions of human early EPCs mediated by activation of the SDF-1<i>α</i>/CXCR4 system. EPCs are in green, bone marrow-derived progenitor cells are in purple, and vascular ECs are in red. CXCR4, C-X-C chemokine receptor type 4; ECs, endothelial cells; EPCs, endothelial progenitor cells; PI3K, phosphoinositide 3-kinase; SDF-1<i>α</i>, stromal cell-derived factor-1<i>α</i>.</div>

BioMed Research International

fig8

Figure 8

Figure 8: Cilostazol Improves Proangiogenesis Functions in Human Early Endothelial Progenitor Cells through the Stromal Cell-Derived Factor System and Hybrid Therapy Provides a Synergistic Effect<i> In Vivo</i> 

Figure 8 | Cilostazol Improves Proangiogenesis Functions in Human Early Endothelial Progenitor Cells through the Stromal Cell-Derived Factor System and Hybrid Therapy Provides a Synergistic Effect In Vivo 